FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549
-------------	------	-------

STATEMENT	OF CHANGES	IN BENEFICIAL	OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL								
OMB Number:	3235-0287							
Estimated average burden								
hours per response:	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person*  O'Mahony John Mark				2. Issuer Name and Ticker or Trading Symbol LEAP THERAPEUTICS, INC. [ LPTX ]						(Ch	Relationship of eck all applic Directo	able)	g Pers	on(s) to Issu 10% Ov Other (s	vner		
(Last) (First) (Middle) C/O LEAP THERAPEUTICS, INC. 47 THORNDIKE STREET, SUITE B1-1				3. Date of Earliest Transaction (Month/Day/Year) 01/31/2022							X Officer (give title below)  Chief Manufacturing Officer				·		
(Street) CAMBR (City)		//A State)	02141 (Zip)		4. If Amendment, Date of Original Filed (Month/Day/Year)					Lin	e) X Form fi Form fi						
		Ta	ble I - Nor	n-Deriv	ative	Securitie	s Ac	quired,	Dis	posed o	of, or Be	neficiall	y Owned				
1. Title of Security (Instr. 3)  2. Transa Date (Month/D			Execution Date,		Code (Instr.		ed (A) or str. 3, 4 and	5. Amour Securitie Beneficia Owned F Reported	s Form ally (D) or ollowing (I) (In		: Direct Indirect str. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)					
							Code	v	Amount	(A) o (D)	r Price	Transacti	Transaction(s) (Instr. 3 and 4)			(111341.4)	
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																	
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security		3A. Deemed Execution Date if any (Month/Day/Ye	Co		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)	e s ally	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)	
				Cod	de V	(A)	(D)	Date Exercisal		Expiration Date	Title	Amount or Number of Shares		(Instr. 4)			
Restricted Stock	\$0 <sup>(1)</sup>	01/31/2022		I	A	225,000		(2)		(2)	Common Stock	225,000	\$0 <sup>(1)</sup>	225,00	00	D	

## **Explanation of Responses:**

- 1. The Restricted Stock Units were awarded pursuant to Leap's 2016 Equity Incentive Plan for no consideration. Restricted Stock Units will be settled in common stock.
- 2. The Restricted Stock Units will cliff vest and be settled after three years of continuous service or upon a change of control of Leap, whichever is earlier.

/s/ Douglas E. Onsi, as attorneyin-fact for John Mark 02/02/2022

O'Mahony

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.